ImmunisLogoWhiteImmunisLogoImmunisLogoMobileImmunisLogoMobile
  • Home
  • About Us
    • Mission
    • Technology
    • Leadership
  • Resources
    • About multi-active biologics
    • About IMM01-STEM
    • About sarcopenia
    • Interested in a clinical trial?
  • Pipeline
    • STEM-MYO Program
      • Phase 1/2a Clinical Trial
    • STEM-META Program
      • Phase 2 Clinical Trial
  • News
    • Awards
    • Media
    • Press Releases
  • Contact
✕

Revolutionizing
Longevity with
Multi-active
Biologics
Immunis is a clinical-stage biotech developing a clinically advanced, first-in-class multi-active therapeutic targeting the underlying factors of aging that drive muscle and metabolic disease. IMM01-STEM is an off-the-shelf investigational product, a complex biologic comprised of stem cell-derived regenerative factors that impact multiple signaling pathways. Immunis is dedicated to maximizing health span and to minimizing disease through the advancement of transformative medicine. Learn More
Muscle -
the Motor
of Longevity
Muscle health is a critical determinant of your quality of life. IMM01-STEM aims to regenerate muscle and enhance muscle function, giving you the strength to maintain independence as you age. Learn more

Recent News

  • Jun 25, 2026

    Immunis Unveils New Brand Identity, Reinforcing Mission to Advance Multi-active Biologics for Muscle Health and Healthy Aging

  • Mar 5, 2026

    Immunis Licenses Treatment Candidate for Dyskinesia Associated with Parkinson’s Disease

  • Jan 14, 2026

    Immunis Announces Preliminary Results from First-Ever Phase 2 Study of a Secretome-Based Biologic Showing Improved Gait Speed in Obese Sarcopenic Seniors

Navigation

  • Home
  • About Us
    • Mission
    • Technology
    • Leadership
  • Resources
  • Pipeline
  • News
    • Awards
    • Media
    • Press Releases
  • Contact

Contact info

Immunis, Inc.
Irvine, California


contact@immunisbiomedical.com

Copyright © 2026 Immunis, Inc.